Success Metrics

Clinical Success Rate
92.9%

Based on 235 completed trials

Completion Rate
93%(235/253)
Active Trials
31(9%)
Results Posted
63%(148 trials)
Terminated
18(5%)

Phase Distribution

Ph phase_3
126
37%
Ph phase_4
80
24%
Ph phase_2
64
19%
Ph early_phase_1
1
0%
Ph phase_1
19
6%
Ph not_applicable
13
4%

Phase Distribution

20

Early Stage

64

Mid Stage

206

Late Stage

Phase Distribution303 total trials
Early Phase 1First-in-human
1(0.3%)
Phase 1Safety & dosage
19(6.3%)
Phase 2Efficacy & side effects
64(21.1%)
Phase 3Large-scale testing
126(41.6%)
Phase 4Post-market surveillance
80(26.4%)
N/ANon-phased studies
13(4.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.7%

235 of 268 finished

Non-Completion Rate

12.3%

33 ended early

Currently Active

31

trials recruiting

Total Trials

340

all time

Status Distribution
Active(44)
Completed(235)
Terminated(33)
Other(28)

Detailed Status

Completed235
unknown28
Recruiting21
Terminated18
Withdrawn15
Not yet recruiting12

Development Timeline

Analytics

Development Status

Total Trials
340
Active
31
Success Rate
92.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.3%)
Phase 119 (6.3%)
Phase 264 (21.1%)
Phase 3126 (41.6%)
Phase 480 (26.4%)
N/A13 (4.3%)

Trials by Status

completed23569%
enrolling_by_invitation10%
unknown288%
active_not_recruiting103%
terminated185%
recruiting216%
not_yet_recruiting124%
withdrawn154%

Recent Activity

Clinical Trials (340)

Showing 20 of 340 trialsScroll for more
NCT06180382Phase 4

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

Recruiting
NCT07061574Phase 1

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Recruiting
NCT04088409Phase 3

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Active Not Recruiting
NCT03412747Phase 3

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
NCT06016517

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

Not Yet Recruiting
NCT06996652Phase 2

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

Not Yet Recruiting
NCT02113904Phase 2

Clinical Trial Using Humira in Netherton Syndrome

Completed
NCT07491913Not Applicable

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

Recruiting
NCT02840175Phase 3

Treatment Tapering in JIA With Inactive Disease

Completed
NCT04527380Phase 3

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Active Not Recruiting
NCT06045754Phase 4

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
NCT06037811Phase 2

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Recruiting
NCT06100744Phase 3

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Recruiting
NCT07398651Not Applicable

Apremilast and Adalimumab in Psoriatic Arthritis Patients

Not Yet Recruiting
NCT06941376Phase 2

An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Recruiting
NCT03895203Phase 3

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Completed
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT02586831Phase 1

Diabetes Islet Preservation Immune Treatment

Withdrawn
NCT05814627Phase 3

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Active Not Recruiting
NCT01895764Phase 4

Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
340